Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Trial Details

NCT ID

NCT06686030

Phase

PHASE2

Sponsor

Akeso

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• AK112 low dose
• Chemotherapy
• Olaparib
• AK112 high dose

Locations (sample)

• Wuhan, China|30.58333,114.26667

Key Eligibility Criteria

• Signs the written informed consent form.
• Female participants who are at least 18 years of age on the day of signing informed consent with.
• ECOG of 0 or 1.
• Life expectancy ≥3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.